‹ Screener

ICON PLC

ICLR · Services-Commercial Physical & Biological Research · EDGAR filings ↗

Grade

C62

Large global CRO with strong cash flow but a financial restatement, material weakness and sharply lower earnings.

Strengths

Risks

Notable findings

Quarterly revenue

2024-12-31 · $2.1B2025-03-31 · $2.0B2025-12-31 · $2.1B2026-03-31 · $2.0B

Last 4 quarters · from SEC filings.

Key metrics

Operating margin
5.4%
Net margin
2.8%
Return on equity
2.5%
Return on assets
1.4%
ROIC
2.9%
Revenue growth (QoQ)
-3.7%
Net-income growth
-69.0%
Debt / equity
0.3×
Net debt / EBITDA
2.7×
Current ratio
1.1×
Free cash flow
$862M
EBITDA
$826M
Tangible book value
-$2.8B
Cash & investments
$647M
Stock comp / revenue
1.2%

Recent filings

FormFiledPeriodAccession
20-F2026-05-272025-12-310001628280-26-038487 ↗
20-F2025-02-212024-12-310001060955-25-000016 ↗
20-F2024-02-232023-12-310001060955-24-000010 ↗
20-F2023-02-242022-12-310001060955-23-000007 ↗
20-F2022-03-012021-12-310001060955-22-000005 ↗
20-F2021-02-242020-12-310001060955-21-000004 ↗
20-F2020-02-272019-12-310001060955-20-000004 ↗
20-F2019-03-012018-12-310001060955-19-000004 ↗
20-F2018-02-282017-12-310001060955-18-000006 ↗
20-F2017-02-282016-12-310001157523-17-000663 ↗
20-F2016-03-232015-12-310001157523-16-004979 ↗
20-F2015-03-122014-12-310001157523-15-000917 ↗